Oncology Billing — Chemo, Biologics & J-Codes, Billed Right

Proven Results

• 40% Average Revenue Increase
• 93.6% First-Pass Claim Rate
• 49% Reduction in Denials
• 20 Days Faster Payment Collection

Common Billing Challenges

Chemotherapy Infusion Coding Complexity

Multiple drug administrations require proper sequencing with initial, concurrent, and sequential codes that must follow strict hierarchy rules.

J-Code Drug Billing

Expensive chemotherapy drugs require accurate J-code billing with proper units, wastage documentation, and HCPCS code selection.

Prior Authorization for Biologics

High-cost biologic medications and immunotherapies require extensive prior authorizations with detailed medical necessity documentation.

Multiple Drug Administration Sequencing

When multiple drugs are administered in one visit, proper CPT code hierarchy must be followed for initial, concurrent, and subsequent infusions.

Radiation Therapy Complex Planning

Radiation oncology involves complex planning codes, simulation charges, dosimetry, and daily treatment management that must be properly billed.

Clinical Trial Coverage Determination

Distinguishing between research-covered services and patient-billable routine care in clinical trials requires careful analysis.

Our Solutions

Oncology-Certified Billing Specialists

Our team includes certified coders with specialized training in oncology billing, chemotherapy administration, and radiation therapy coding.

• Expert CPT coding for all oncology services
• Chemotherapy sequencing expertise
• J-code and HCPCS drug billing knowledge
• Radiation therapy planning codes

Infusion Hierarchy Management

Comprehensive understanding of chemotherapy administration hierarchy ensures proper initial, concurrent, and sequential code application.

• Accurate infusion sequencing
• Push vs infusion determination
• Concurrent therapy coding
• Hydration and supportive care billing

Prior Authorization Coordination

Dedicated team manages complex prior authorizations for expensive biologics, immunotherapies, and targeted cancer treatments.

• Faster biologic approvals
• Medical necessity documentation
• Peer-to-peer support
• Reduced treatment delays

Drug & Supply Cost Recovery

Ensure full reimbursement for expensive chemotherapy drugs, biologics, and oncology supplies with proper J-code billing and wastage documentation.

• Accurate J-code selection
• Wastage documentation guidance
• Buy-and-bill optimization
• Unit calculation accuracy

Specialized Services

Chemotherapy Administration

Expert billing for IV push, infusion, intra-arterial, and subcutaneous chemotherapy with proper sequencing and drug coding.

• IV infusion (96413-96417)
• IV push administration
• Concurrent therapy
• Sequential drug administration

Immunotherapy & Biologics

Specialized billing for immunotherapy infusions, biologic medications, and targeted cancer therapies with J-code expertise.

• Immunotherapy infusions
• Monoclonal antibodies
• CAR-T cell therapy
• Targeted biologic drugs

Radiation Oncology

Comprehensive billing for radiation therapy planning, simulation, dosimetry, treatment delivery, and management services.

• Treatment planning (77295-77301)
• Simulation (77280-77295)
• Dosimetry calculations
• Treatment management

Oncology Drug Billing

Accurate billing for chemotherapy drugs, supportive medications, and oncology supplies with proper J-code and HCPCS coding.

• J-code drug billing
• Supportive care drugs
• Antiemetic administration
• Drug wastage documentation

Common CPT Codes Reference

Key codes include 96413 (Chemotherapy, IV infusion, initial up to 1 hour), 96415 (Chemotherapy, IV infusion, each additional hour), 96401 (Chemotherapy, subcutaneous or intramuscular injection), 96402 (Chemotherapy, hormonal antineoplastic injection), 96365 (IV infusion, therapeutic/diagnostic, initial up to 1 hour), 77385 (Intensity-modulated radiation therapy delivery (IMRT)), 77263 (Therapeutic radiology treatment planning, complex), 99213 (Office visit, established patient, 20–29 min), 99214 (Office visit, established patient, 30–39 min), 86316 (Immunoassay for tumor antigen — quantitative (CA 19-9)). Proper code selection requires understanding of bundling rules, NCCI edits, and modifier usage.

Expert Billing Insights

Oncology Drug Buy-and-Bill: J-Codes, Wastage, and Site of Service

Medical oncology practices that administer chemotherapy and biologic agents in-office operate on the buy-and-bill model, purchasing drugs at acquisition cost and billing insurance at the published J-code rate. The "spread" between acquisition cost and reimbursement is a major revenue driver. Proper billing requires knowing the exact dose administered in milligrams or units, the NDC number for audit purposes, and documentation of single-dose vial wastage. Site-of-service differences (POS 11 vs. POS 22) significantly affect drug reimbursement.

• ASP + 6%: Medicare formula for Part B drug reimbursement in physician office settings
• Bill exact dose administered in units matching the J-code descriptor — not vial size
• Document vial wastage for any unused portion of single-dose vials
• Hospital outpatient (POS 22) chemotherapy reimburses at APC rates — often higher than physician office

Immunotherapy and Targeted Therapy Billing

The oncology landscape has shifted dramatically toward immunotherapy (checkpoint inhibitors) and targeted therapies (tyrosine kinase inhibitors, CDK4/6 inhibitors). These agents have unique billing characteristics: infused checkpoint inhibitors (pembrolizumab, nivolumab, atezolizumab) are billed as Part B drugs; oral targeted therapies (ibrutinib, palbociclib, osimertinib) are Part D drugs requiring specialty pharmacy coordination. Understanding which pathway each drug follows prevents billing errors and ensures patients receive correct cost-sharing information.

• Pembrolizumab: J9271 per mg; nivolumab: J9299; atezolizumab: J9022 — verify current codes
• Oral oncolytics: NOT billable under Part B — patient must use Part D specialty pharmacy
• CAR-T therapy (tisagenlecleucel, axicabtagene): Q2055, Q2041 — hospital-administered only
• REMS programs for certain oncolytics require documentation of enrollment and counseling

Oncology Value-Based Care: OCM, MIPS, and Quality Programs

The Oncology Care Model (OCM) and its successors (EOM) represent CMS's push toward value-based oncology reimbursement. Practices in these programs receive enhanced per-beneficiary-per-month (PBPM) payments and share in savings when total episode costs are below benchmark. Documentation requirements include treatment summaries, survivorship care plans, patient navigation services, and quality measure reporting. Outside formal programs, MIPS oncology quality measures drive up to 9% Medicare payment adjustments.

• Enhanced PBPM: document monthly touchpoints, treatment summaries, and care coordination
• Survivorship care plan: document within 6 months of treatment completion for quality credit
• Patient navigation (G6001–G6015): billable care coordination for oncology patients
• MIPS oncology measures: proportion on chemotherapy receiving anti-emetics per guideline

Payer-Specific Billing Tips

Medicare Part B

• Chemotherapy drugs reimbursed at ASP+6% — track ASP updates quarterly
• Anti-nausea drugs administered with chemo (ondansetron, granisetron): covered under Part B
• Oral chemotherapy coverage gap: Part D covers oral chemo but not at same rate as IV — disparities exist
• Medicare requires oncology advance directives documentation — POLST/DNR affects quality measures

Medicaid

• Cancer treatment prior authorization requirements vary significantly by state Medicaid plan
• Pediatric oncology: aggressive coverage under EPSDT — CAR-T may be covered for pediatric ALL
• Generic chemotherapy agents typically on preferred formulary — biologics require prior auth
• Medicaid managed care oncology networks may be narrower — verify network participation

Commercial Payers

• All chemotherapy and biologic regimens require prior authorization with clinical rationale
• Reference treatment guidelines (NCCN, ASCO) in prior auth submissions for evidence-based support
• Compassionate use and off-label biologics: submit literature with prior auth request
• Commercial plans may require preferred oncology network or COE (Center of Excellence) participation

Radiation Oncology

• Radiation billing: separate professional (radiation oncologist) and technical (facility) components
• IMRT planning and delivery codes are bundled — do not separately bill simulation from planning
• Proton therapy requires NCD review and prior auth from most payers
• Palliative radiation for pain: document pain level, functional status, and expected fractions

Related Billing Resources

• Hematology Billing
• Pulmonology Billing
• Pathology & Lab Billing
• Prior Authorization Services
• Denial Management Services
• CPT Codes Reference Guide
• ICD-10 Codes Reference

Key Services

• oncology billing
• cancer care billing
• chemotherapy billing
• radiation oncology billing
• medical oncology billing
• immunotherapy billing
• J-code billing